Comparison · NCT02249052-0047a5cb
AA4500 vs Placebo: Responder Analysis
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AA4500 vs Placebo: Responder Analysis. Trial comparisons, record NCT02249052-0047a5cb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02249052-0047a5cb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.895 | 0.686 | 0.971 | wilson | |
| Risk in group 2 | 0 | 0 | 0.168 | wilson | |
| Risk difference, group 1 minus group 2 | 0.895 | 0.627 | 0.971 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on AA4500 than on Placebo | 1.12 | 1.03 | 1.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AA4500 | Each subject received a single injection of 1 mL containing 0.58 mg AA4500 | 17 | 19 | OG000 |
| Group 2 | Placebo | Each subject received a single injection of 1 mL placebo | 0 | 19 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Responder Analysis
- Description
- The number of participants with at least 50% decrease in visible lipoma surface area of lipoma relative to baseline
- Time frame
- Baseline and 6 months
- Population
- All 19 participants
Source ClinicalTrials.gov
Trial
- Title
- Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma
- NCT number
- NCT02249052
- Phases
- PHASE2
- Conditions
- Lipoma
- Interventions
- AA4500, placebo
- Lead sponsor
- Gerut, Zachary, M.D.
- Results first posted
- 2016-12-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02249052?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02249052-0047a5cb